OTC Watch

All stocks / SIGY

Sigyn Therapeutics, Inc. SIGY

Sigyn Therapeutics (SIGY): convertible notes mentioned in an 8-K in February 2026, a late 10-K notice in March 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Late filingCostly financingEstimated float Pink LimitedCalifornia, USA
Live quote on OTC Markets

Market listing

Full name
SIGYN THERAPEUTICS INC
Market tier
OTC Pink Limited
Trading status
Active
Last trade
Nov 16
Source: Stockwatch, 2026-11-17

News headlines

Oragenics Signs Letter of Intent to License CardioDialysis(TM) Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
2026-05-07 08:30 ยท News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2024-12-31
The report says
Net loss
($3,340,212)
What it means

It spends more than it earns

Under strain

The company lost $3.3 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$12,144
Net cash used in operating activities
($872,436)
What it means

The cash could run out soon

Under strain

It had $12,144 in the bank and used about $72,703 a month. At that pace the money lasts less than a month unless it borrows or sells more shares.

The report says
Total assets
$213,719
Total liabilities
$4,671,343
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $213,719. Its debts and unpaid bills add up to $4.7 million. That is about $21.86 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Late filing2026-03-31

Filed NT 10-K on 2026-03-31: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Costly financing2026-02-20

8-K filed 2026-02-20 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Estimated float2025-11-14

Estimated float about 1,605,377 shares as of 2025-11-14: 1,605,377 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2024-12-31
1.6M
2025-03-31
1.6M
2025-04-11
1.6M
2025-05-20
1.6M
2025-06-30
1.6M
2025-09-05
1.6M
2025-09-30
1.6M
2025-11-14
1.6M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-07-16 15-12G15-12G
2026-03-31 NT 10-KNT 10-K
2026-02-20 8-K8-K
2026-01-14 SCHEDULE 13G/A

Common questions about SIGY

Does SIGY file reports with the SEC?

Yes. Sigyn Therapeutics files with the SEC under company number 0001642159. The most recent filing we hold is a 15-12G dated 2026-07-16.

Source record

How many SIGY shares are outstanding?

1,605,377 shares as of 2025-11-14, as reported to the SEC.

Source record

Has SIGY filed reports late?

Yes. In the last 12 months it filed 1 late-filing notice, most recently a NT 10-K on 2026-03-31. A notice means a report was not ready on time; check whether the report followed.

Source record

Is Sigyn Therapeutics making money?

The company lost $3.3 million in the year. It reported no sales. (Annual figures to 2024-12-31. Facts from the company's own report, not a recommendation.)

Source record